Vir

formerly Vir Biotechnology

Powering the Immune System to Transform Lives

San Francisco, United States · Founded 2016 · $250.0M raised

Employees
201–500
Founded
2016
Business Model
B2B
Website
vir.bio
Total Funding
$250.0M
Last Round
$250.0M Growth EquityOct 2024
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Vir Biotechnology leverages the immense potential of the immune system to address critical unmet medical needs and improve patient outcomes. Its pipeline is built on two technology platforms — a next-generation antibody platform and the PRO-XTEN protease-releasable masking technology — applied to infectious diseases and oncology. The company has broken ground in immunology, engineering antibody-based medicines for COVID-19 and Ebola, with a leading program in chronic hepatitis delta and strategic programs in oncology.

Summary

Vir is a Biotech company based in San Francisco, United States, founded in 2016. It has raised $250.0M in total across 2 rounds, most recently a $250.0M Growth Equity round in Oct 2024. Investors include GV and ARCH Venture Partners.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Secondary MarketSecondaryFeb 2026

Sign up to see all 3 events

Funding: Venture Round through Growth Equity. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Vir on Indexed.vc
<a href="https://indexed.vc/companies/vir"><img src="https://indexed.vc/api/badge/company/vir" alt="Vir on Indexed.vc" width="260" height="76" /></a>